Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiangsu Health Pharmaceutical Investment
Lianyungang, Jiangsu, China
- Ownership
- Private
- Employees
- ~20238
- Development stage
- Other
01
Overview
Hengrui Pharma has 24 new molecular entity drugs marketed in China, over 100 pipeline candidates, ongoing international expansion, multiple recent licenses and partnerships, and is among China's most innovative pharma companies. Top-selling drugs include albumin-binding paclitaxel injection, rezvilutamide, and camrelizumab plus rivoceranib combination.
- Therapeutic areas
- CardiovascularImmunologyPulmonologyNeurologyMetabolic DisordersOncology
- Modalities
- Small moleculeMonoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugateRadiopharmaceuticalPeptidesProteolysis-targeting chimera therapymRNA-based drugsGene therapyExosome-based therapyAI-driven drug discovery
- Industry
- Pharma
02
Partnerships
GSK (12-program collaboration, incl. PDE3/4 inhibitor, RI&I and Oncology)
Beyond the preview
Go deeper on Jiangsu Health Pharmaceutical Investment.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jiangsu Health Pharmaceutical Investment.